Chembio Diagnostics plummets after FDA revokes authorization for its SARS-CoV-2 antibody test Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Aclaris Therapeutics (ACRS) up 62% after announcing that the FDA has allowed an investigational new drug application to evaluate ATI-450 in hospitalized patients with COVID-19
- Energous (WATT) up 76% after announcing a partnership with Grepow Battery to develop batteries that are wirelessly charged via a radio frequency based charging technology
- Tempur Sealy (TPX) up 2% after raising its Q2 revenue outlook
- Fulgent Genetics (FLGT) up 21% after
announcing that it has launched an at-home testing solution for COVID-19
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
ALSO LOWER -
- Chembio Diagnostics (CEMI) down 60% after the FDA revoked the emergency use authorization of the Chembio Diagnostic System DPP COVID-19 IgM/IgG System, a SARS-CoV-2 antibody test, due to performance concerns with the accuracy of the test
- InflaRx (IFRX) down 13% after reporting interim results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 pneumonia
- Aveo Pharmacuticals (AVEO) down 12% after its 8.5M share secondary offering priced at $5.25 per share
- Norwegian Cruise Line (NCLH) down 10% after announcing an extension of its previously announced suspension of global cruise voyages to include all voyages embarking between August 1 and September 30 for its three cruise brands
Symbols:
ACRS WATT TPX FLGT GRPN ORCL IFRX CEMI AVEO NCLH Keywords: Fly Intel, Wall Street, Top Stories, Stocks